Evidence map›Paper›PMID 28488155›Full record

ArticleThe journal of behavioral health services & research2017

Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.

Traci R Rieckmann, Nicholas Gideonse, Amanda Risser, Jennifer E DeVoe, Amanda J Abraham

Abstract read
PubMed Publisher
In one paragraph

Article in The journal of behavioral health services & research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
  5. Article
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Traci R RieckmannOHSU-PSU School of Public Health, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239-3098, USA. rieckman@ohsu.edu.
Nicholas GideonseDepartment of Family Medicine, Oregon Health & Science University, Portland, OR, 97239-3098, USA.
Amanda RisserDepartment of Family Medicine, Oregon Health & Science University, Portland, OR, 97239-3098, USA.
Jennifer E DeVoeOCHIN Community Health Information Network, Portland, OR, 97201-5195, USA.
Amanda J AbrahamDepartment of Public Administration and Policy, University of Georgia, Athens, GA, 30602, USA.
Oregon Health & Science University · USOchin · USUniversity of Georgia · US

Funding

CREATE Community CapacityRC4LM010852 · NLM · OREGON HEALTH & SCIENCE UNIVERSITY · PI SAULTZ, JOHN W · 2010 to 2010
$996k
NLM NIH HHS RC4 LM010852
6 · The paper itself

Abstract

Research has examined the safety, efficacy, feasibility, and cost-effectiveness of buprenorphine for the treatment of opioid dependence, but few studies have examined patient and provider experiences, especially in community health centers. Using de-identified electronic health record system (EHRS) data from 70 OCHIN community health centers (n = 1825), this cross-sectional analysis compared the demographics, comorbidities, and service utilization of patients receiving buprenorphine to those not receiving medication-assisted treatment (MAT). Compared to non-MAT patients, buprenorphine patients were younger and less likely to be Hispanic or live in poverty. Buprenorphine patients were less likely to have Medicaid insurance coverage, more likely to self-pay, and have private insurance coverage. Buprenorphine patients were less likely to have problem medical comorbidities or be coprescribed high-risk medications. It is important for providers, clinic administrators, and patients to understand the clinical application of medications for opioid dependence to ensure safe and effective care within safety net clinics.

Indexed as

AdolescentAdultAge FactorsBuprenorphineCross-Sectional StudiesFemaleHumansInsurance CoverageMaleMiddle AgedNarcotic AntagonistsOpioid-Related DisordersSocioeconomic FactorsYoung AdultBuprenorphineNarcotic Antagonists

Identifiers

PMID28488155
OpenAlexW2612433181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.